Cancer Research and Treatment

Original Articles

General

Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial: Yaewon Yang, Jang-Hee Hahn, Min Seo Kim, Minkwan Jo, Yong-Pyo Lee, Hongsik Kim, Hee Kyung Kim, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han; Cancer Res Treat. 2024;56(4):1050-1057. Published online June 5, 2024; DOI: https://doi.org/10.4143/crt.2024.080

Abstract PDF Supplementary Material PubReader ePub

Purpose
Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are relatively common toxicities that interfere with the quality of life (QoL) of patients with cancer. Anti-inflammatory tripeptide cream (ATPC) is a complex formulation of anti-inflammatory tripeptides, the CD99-agonist Binterin and the Wnt-antagonist Winhibin. The present study aimed to assess the therapeutic effects of ATPC in HFS/HFSR associated with anticancer drugs.
Materials and Methods
This was a single-center, randomized, double-blind, placebo-controlled trial. Patients who developed grade 1 HFS/HFSR after systemic anticancer treatments were enrolled, and randomly assigned to receive either ATPC or placebo cream (PC) and followed up at 3-week intervals for up to 9 weeks. Primary endpoint was the development of grade ≥ 2 HFS/HFSR.
Results
Between April 2019 and July 2022, 60 patients (31 in the ATPC and 29 in the PC group) completed the study. The incidence of grade ≥ 2 HFS/HFSR was significantly lower in the ATPC than in the PC group (25.8% vs. 51.7%, p=0.039). The ATPC showed trends towards a better QoL score, assessed by a HFSR and QoL questionnaire at 9 weeks (26.0 vs. 29.9, p=0.574), and a lower frequency of discontinuation, interruption, or dose reduction of anticancer drugs (51.6% vs. 58.6%, p=0.586) than the PC group over 9 weeks, though without statistical significance.
Conclusion
Our results showed that ATPC significantly decreased the development of grade ≥ 2 HFS/HFSR in patients already with HFS/HFSR. Therefore, ATPC may be an effective treatment for HFS/HFSR associated with anticancer drugs.

Citations

Citations to this article as recorded by

The Effect of Topical Heparin Gel on Reducing Hand–Foot Syndrome Symptoms in Cancer Patients Treated with Capecitabine
Maede Mirjalili, Yaser Salehinajafabadi, Hadi Raeisi Shahraki, Rohollah Masumi
South Asian Journal of Cancer.2025;[Epub] CrossRef

2,193 View
193 Download
1 Web of Science
1 Crossref

Endocrine cancer

Phase 1 Study of No-Carrier Added ¹⁷⁷Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor–Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea: Hyun Gee Ryoo, Minseok Suh, Keon Wook Kang, Dae-Won Lee, Sae-Won Han, Gi Jeong Cheon; Cancer Res Treat. 2023;55(1):334-343. Published online April 22, 2022; DOI: https://doi.org/10.4143/crt.2021.1022

Abstract PDF Supplementary Material PubReader ePub

Purpose
To provide a wider choice of treatment opportunities for patients with neuroendocrine tumor (NET) in Korea, we have conducted a phase 1, open-label, single-arm, dose-escalation study of SNU-KB-01, a no-carrier added (NCA) ¹⁷⁷Lu-labeled DOTATATE.
Materials and Methods
Seven patients with inoperable, progressive, metastatic, or locally advanced, somatostatin receptor-positive NET with Ki67 index ≤ 20% were enrolled according to the rolling six design. The study consisted of two cohorts to receive 4 cycles of SNU-KB-01 every 8 weeks for the first dose of 5.55 GBq (n=3) and 7.40 GBq (n=4). We assessed the incidence of dose-limiting toxicity (DLT) and adverse event, absorbed dose of kidneys and bone marrow, and objective tumor response.
Results
Seven patients completed 4 cycles (21.3-30.1 GBq total dose) of SNU-KB-01. The mean absorbed doses to kidneys and bone marrow were 0.500 mGy/MBq and 0.053 mGy/MBq, respectively, and the total body effective dose was 0.115 mSv/MBq. No DLT was observed and the maximum tolerated dose was 7.40 GBq/cycle. Grade 3 thrombocytopenia occurred in one patient, but no other grade 3 or 4 major hematologic or renal toxicity was observed. The best objective response to SNU-KB-01 was partial response. Overall response rate was 42.9% and disease control rate was 85.7%.
Conclusion
Treatment with 4 cycles of SNU-KB-01 was well tolerated and resulted in control of disease in most of the patients. Our results indicate SNU-KB-01, an NCA ¹⁷⁷Lu-labeled DOTATATE, as a potentially safe and efficacious treatment option for NET patients in Korea.

Citations

Citations to this article as recorded by

Peptide-drug conjugates: A new paradigm for targeted cancer therapy
Mo Wang, Jiawei Liu, Mingjing Xia, Libinghan Yin, Ling Zhang, Xifu Liu, Yu Cheng
European Journal of Medicinal Chemistry.2024; 265: 116119. CrossRef
Electrochemical separation and purification of no-carrier-added 177Lu for radiopharmaceutical preparation: Translation from bench to bed
Sourav Patra, Rubel Chakravarty, Khajan Singh, K.V. Vimalnath, Sudipta Chakraborty
Chemical Engineering Journal Advances.2023; 14: 100444. CrossRef

5,770 View
208 Download
2 Web of Science
2 Crossref

General

Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy: Yilei Chen, Hongxing Huang, Yin Liu, Zhanghao Wang, Lili Wang, Quanxiao Wang, Yan Zhang, Hua Wang; Cancer Res Treat. 2022;54(2):362-374. Published online August 3, 2021; DOI: https://doi.org/10.4143/crt.2021.424

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to optimize a peptide (nABP284) that binds to programmed cell death protein 1 (PD-1) by a computer-based protocol in order to increase its affinity. Then, this study aimed to determine the inhibitory effects of this peptide on cancer immune escape by coculturing improving cytokine-induced killer (ICIK) cells with cancer cells.
Materials and Methods
nABP284 that binds to PD-1 was identified by phage display technology in our previous study. AutoDock and PyMOL were used to optimize the sequence of nABP284 to design a new peptide (nABPD1). Immunofluorescence was used to demonstrate that the peptides bound to PD-1. Surface plasmon resonance was used to measure the binding affinity of the peptides. The blocking effect of the peptides on PD-1 was evaluated by a neutralization experiment with human recombinant programmed death-ligand 1 (PD-L1) protein. The inhibition of activated lymphocytes by cancer cells was simulated by coculturing of human acute T lymphocytic leukemia cells (Jurkat T cells) with human tongue squamous cell carcinoma cells (Cal27 cells). The anticancer activities were determined by coculturing ICIK cells with Cal27 cells in vitro.
Results
A high-affinity peptide (nABPD1, K_D=11.9 nM) for PD-1 was obtained by optimizing the nABP284 peptide (K_D=11.8 μM). nABPD1 showed better efficacy than nABP284 in terms of increasing the secretion of interkeulin-2 by Jurkat T cells and enhancing the in vitro antitumor activity of ICIK cells.
Conclusion
nABPD1 possesses higher affinity for PD-1 than nABP284, which significantly enhances its ability to block the PD-1/PD-L1 interaction and to increase ICIK cell-mediated antitumor activity by armoring ICIK cells.

Citations

Citations to this article as recorded by

Peptide‑based therapeutic strategies for glioma: Current state and prospects
Yajing Mi, Pengtao Jiang, Jing Luan, Lin Feng, Dian Zhang, Xingchun Gao
Peptides.2025; 185: 171354. CrossRef
Development of Novel Short Peptide Inhibitor Targeted to Immune Checkpoint PD-1 LBD
Xingyan Zhu, Yuping Wei, Man Zhang, Kun Liu, Ziyang Liu, Qiuhong Niu
International Journal of Peptide Research and Therapeutics.2025;[Epub] CrossRef
A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC
Lili Wang, Junheng Zheng, Zhihao Tan, Yan Zhang, Hua Wang
International Immunopharmacology.2024; 138: 112582. CrossRef
Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice
Shanshan (Jenny) Zhong, Xiaoling Liu, Tomonori Kaneko, Yan Feng, Owen Hovey, Kyle Yang, Sally Ezra, Soon-Duck Ha, Sung Kim, John K. McCormick, Huadong Liu, Shawn Shun-Cheng Li
Cells.2024; 13(14): 1193. CrossRef
Melittin-incorporated nanomedicines for enhanced cancer immunotherapy
Xuefeng Duan, Haoyang Zou, Jiazhen Yang, Shixian Liu, Tianmin Xu, Jianxun Ding
Journal of Controlled Release.2024; 375: 285. CrossRef
Peptides as multifunctional players in cancer therapy
Sri Murugan Poongkavithai Vadevoo, Smriti Gurung, Hyun-Su Lee, Gowri Rangaswamy Gunassekaran, Seok-Min Lee, Jae-Won Yoon, Yun-Ki Lee, Byungheon Lee
Experimental & Molecular Medicine.2023; 55(6): 1099. CrossRef
Progress of research on PD-1/PD-L1 in leukemia
Huizhen Cao, Tianyu Wu, Xue Zhou, Shuyang Xie, Hongfang Sun, Yunxiao Sun, Youjie Li
Frontiers in Immunology.2023;[Epub] CrossRef
Development of PD-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia
Quanxiao Wang, Hongxing Huang, Peisheng Liang, Lili Wang, Junheng Zheng, Yan Zhang, Hua Wang
Medical Oncology.2023;[Epub] CrossRef
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
Won Suk Lee, Dong Sung Kim, Jeong Hun Kim, Yoonki Heo, Hannah Yang, Eun-Jin Go, Jin Hyoung Kim, Seung Joon Lee, Byung Cheol Ahn, Jung Sun Yum, Hong Jae Chon, Chan Kim
Journal for ImmunoTherapy of Cancer.2022; 10(6): e004799. CrossRef

11,312 View
302 Download
10 Web of Science
9 Crossref

Review Article

Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion: Changhoon Yoo, Chung Ryul Oh, Seung-Tae Kim, Woo Kyun Bae, Hye-Jin Choi, Do-Youn Oh, Myung-Ah Lee, Baek-Yeol Ryoo; Cancer Res Treat. 2021;53(2):291-300. Published online December 29, 2020; DOI: https://doi.org/10.4143/crt.2020.1233

Abstract PDF PubReader ePub

Neuroendocrine tumors (NETs) are a group of malignancies arising from neuroendocrine cells and frequently originate in the gastrointestinal tract and pancreas. Although curative resection is the main treatment for localized disease, systemic therapy is needed for relapsed or metastatic/unresectable gastroenteropancreatic NETs (GEP-NETs). Although there are several NET treatment guidelines from various countries, the geographical discrepancies between patient clinical characteristics, the regulatory approval status for therapeutic agents, and medical practices necessitate specific guidelines for Korean patients. We here provide a consensus review of the diagnosis, staging and systemic treatment of Korean GEP-NET patients. Systemic therapy options and the current Korean expert consensus on these treatments, including somatostatin analogs, targeted therapies such as everolimus and sunitinib, peptide receptor radionuclide treatments, and cytotoxic chemotherapies are addressed.

Citations

Citations to this article as recorded by

Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
Yeokyeong Shin, Bo Hyun Moon, Baek-Yeol Ryoo, Heung-Moon Chang, Kyu-pyo Kim, Yong Sang Hong, Tae Won Kim, Jin-Sook Ryu, Yong-il Kim, Changhoon Yoo
Targeted Oncology.2024; 19(1): 41. CrossRef
Effectiveness and Safety of Retreatment with177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States
Ebrahim S. Delpassand, Soheil M. Yazdi, Shashank Ghantoji, Antonio Nakasato, Corinne Strickland, Rodolfo Nunez, Afshin Shafie, Susan Cork, Clare Byrne, Jackson Tang, Jeetvan Patel
Journal of Nuclear Medicine.2024; 65(5): 746. CrossRef
Advances in hydrogel materials applied to pancreatic-related diseases
Yuan Zhou, Maoen Pan, Ronggui Lin, Heguang Huang
Journal of Pancreatology.2024; 7(3): 222. CrossRef
Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy
Eonwoo Shin, Yong-il Kim, Changhoon Yoo, Yeokyeong Shin, Baek-Yeol Ryoo, Dong Yun Lee, Jin-Sook Ryu
European Radiology.2024; 35(5): 2559. CrossRef
Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors
Boris G. Naraev, Josh Mailman, Thorvardur R. Halfdanarson, Heloisa P. Soares, Erik S. Mittra, Julie Hallet
Expert Review of Anticancer Therapy.2023; 23(6): 601. CrossRef
KSNM60 in Nuclear Endocrinology: from the Beginning to the Future
Chae Moon Hong, Young Jin Jeong, Hae Won Kim, Byeong-Cheol Ahn
Nuclear Medicine and Molecular Imaging.2022; 56(1): 17. CrossRef
Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
Eun-Joo Park, Hyo-Jung Park, Kyung-Won Kim, Chong-Hyun Suh, Changhoon Yoo, Young-Kwang Chae, Sree Harsha Tirumani, Nikhil H. Ramaiya
Cancers.2022; 14(3): 794. CrossRef
Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
Krzysztof Kaliszewski, Maksymilian Ludwig, Maria Greniuk, Agnieszka Mikuła, Karol Zagórski, Jerzy Rudnicki
Cancers.2022; 14(8): 2028. CrossRef
Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
H. Jeong, J. Shin, J.H. Jeong, K.-p. Kim, S.-M. Hong, Y.-i. Kim, J.-S. Ryu, B.-Y. Ryoo, C. Yoo
ESMO Open.2021; 6(3): 100119. CrossRef

10,767 View
386 Download
10 Web of Science
9 Crossref

Original Articles

A Phage Display-Identified Peptide Selectively Binds to Kidney Injury Molecule-1 (KIM-1) and Detects KIM-1-Overexpressing Tumors in vivo: Md. Enamul Haque, Fatima Khan, Lianhua Chi, Smriti Gurung, Sri Murugan Poongkavithai Vadevoo, Rang-Woon Park, Dong-Kyu Kim, Sang Kyoon Kim, Byungheon Lee; Cancer Res Treat. 2019;51(3):861-875. Published online October 1, 2018; DOI: https://doi.org/10.4143/crt.2018.214

Abstract PDF PubReader ePub

Purpose
This study was carried out to identify a peptide that selectively binds to kidney injury molecule-1 (KIM-1) by screening a phage-displayed peptide library and to use the peptide for the detection of KIM-1overexpressing tumors in vivo.
Materials and Methods
Biopanning of a phage-displayed peptide library was performed on KIM-1–coated plates. The binding of phage clones, peptides, and a peptide multimer to the KIM-1 protein and KIM-1–overexpressing and KIM-1–low expressing cells was examined by enzyme-linked immunosorbent assay, fluorometry, and flow cytometry. A biotin-peptide multimer was generated using NeutrAvidin. In vivo homing of the peptide to KIM-1–overexpressing and KIM1–low expressing tumors in mice was examined by whole-body fluorescence imaging.
Results
A phage clone displaying the CNWMINKEC peptide showed higher binding affinity to KIM-1 and KIM-1–overexpressing 769-P renal tumor cells compared to other phage clones selected after biopanning. The CNWMINKEC peptide and a NeutrAvidin/biotin-CNWMINKEC multimer selectively bound to KIM-1 over albumin and to KIM-1–overexpressing 769-P cells and A549 lung tumor cells compared to KIM-1-low expressing HEK293 normal cells. Co-localization and competition assays using an anti–KIM-1 antibody demonstrated that the binding of the CNWMINKEC peptide to 769-P cells was specifically mediated by KIM-1. The CNWMINKEC peptide was not cytotoxic to cells and was stable for up to 24 hours in the presence of serum. Whole-body fluorescence imaging demonstrated selective homing of the CNWM-INKEC peptide to KIM-1–overexpressing A498 renal tumor compared to KIM1–low expressing HepG2 liver tumor in mice.
Conclusion
The CNWMINKEC peptide is a promising probe for in vivo imaging and detection of KIM-1‒overexpressing tumors.

Citations

Citations to this article as recorded by

Advances in Homing Peptide Targeted Therapies
Xiaohong Xian, Qingmiao Ren, Haiyun Du, Yaya Qi, Jiexi Yan
International Journal of Peptide Research and Therapeutics.2025;[Epub] CrossRef
Bi-functional KIT-PR1P peptides combine with VEGF to protect ischemic kidney in rats by targeting to Kim-1
Runxue Zhou, Hang Liu, Xianglin Hou, Qi Liu, Shuwei Sun, Xiaoge Li, Wenxuan Cao, Weihong Nie, Chunying Shi, Wei Chen
Regenerative Therapy.2024; 25: 162. CrossRef
Improving Pharmacokinetics of Peptides Using Phage Display
Mallika Asar, Jessica Newton-Northup, Mette Soendergaard
Viruses.2024; 16(4): 570. CrossRef
Unveiling Invisible Extracellular Vesicles: Cutting‐Edge Technologies for Their in Vivo Visualization
Prakash Gangadaran, Fatima Khan, Ramya Lakshmi Rajendran, Akanksha Onkar, Anshika Goenka, Byeong‐Cheol Ahn
WIREs Nanomedicine and Nanobiotechnology.2024;[Epub] CrossRef
Modified Bacteriophage for Tumor Detection and Targeted Therapy
Yuanzhao Shen, Jingyu Wang, Yuting Li, Chih-Tsung Yang, Xin Zhou
Nanomaterials.2023; 13(4): 665. CrossRef
Tumor microenvironment signaling and therapeutics in cancer progression
Anshika Goenka, Fatima Khan, Bhupender Verma, Priyanka Sinha, Crismita C. Dmello, Manasi P. Jogalekar, Prakash Gangadaran, Byeong‐Cheol Ahn
Cancer Communications.2023; 43(5): 525. CrossRef
Specific bFGF targeting of KIM-1 in ischemic kidneys protects against renal ischemia-reperfusion injury in rats
Siqi Song, Xianglin Hou, Weiwei Zhang, Xinyu Liu, Wei Wang, Xiaoya Wang, Wenxuan Cao, Yujun Xia, Wei Chen, Chunying Shi
Regenerative Biomaterials.2022;[Epub] CrossRef
Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy
Chunyan Li, Jia Li, Ying Xu, Ying Zhan, Yu Li, Tingting Song, Jiao Zheng, Hong Yang
International Journal of Peptide Research and Therapeutics.2021; 27(1): 587. CrossRef
Detection of kidney disease biomarkers based on fluorescence technology
Bicheng Yao, Marie-Claire Giel, Yuning Hong
Materials Chemistry Frontiers.2021; 5(5): 2124. CrossRef
Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library
Shuhui Zhao, Chunyan Li, Yunge Gao, Luomeng Qian, Jian Dong, Lianghao Zhai, Biliang Chen, Jianfang Zhang
International Journal of Peptide Research and Therapeutics.2021; 27(3): 1741. CrossRef

10,791 View
401 Download
12 Web of Science
10 Crossref

Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same: Vishal Sahu, Lokesh Nigam, Vertica Agnihotri, Abhishek Gupta, Shashank Shekhar, Naidu Subbarao, Suman Bhaskar, Sharmistha Dey; Cancer Res Treat. 2019;51(1):313-325. Published online May 9, 2018; DOI: https://doi.org/10.4143/crt.2018.105

Abstract PDF Supplementary Material PubReader ePub

Purpose
The p38 mitogen-activated protein kinase (MAPKs) play a crucial role in the production of pro-inflammatory cytokines and over-expression of it increase cytokines which promote cancer. Among four isoforms, p38α has been well studied in head and neck squamous cell carcinoma (HNSCC) and other cancers as a therapeutic target. p38δ has recently emerged as a potential disease-specific drug target. Elevated serum p38α level in HNSCC was reported earlier from our lab. This study aims to estimate the levels of p38 MAPK-isoforms in the serum of HNSCC and design peptide inhibitor targeting the same.
Materials and Methods
Levels of p38 MAPK isoforms in the serum of HNSCC and healthy controls were quantified by surface plasmon resonance technology. The peptide inhibitor for p38 MAPK was designed by molecular modeling using Grid-based Ligand Docking with Energetics tools and compared with known specific inhibitors.
Results
We have observed highly elevated levels of all four isoforms of p38 MAPK in serum of HNSCC patients compared to the control group. Further, serum p38α, p38β, and p38δ levels were down regulated after therapy in follow-up patients, while p38γ showed no response to the therapy. Present study screened designed peptide WFYH as a specific inhibitor against p38δ. The specific inhibitor of p38δ was found to have no effect on p38α due to great structural difference at ATP binding pocket.
Conclusion
In this study, first time estimated the levels of p38 MAPK isoforms in the serum of HNSCC. It can be concluded that p38 MAPK isoforms can be a diagnostic and prognostic marker for HNSCC and p38δ as a therapeutic target.

Citations

Citations to this article as recorded by

Xuefu Zhuyu Decoction improves hyperlipidemia through the MAPK/NF‐κB and MAPK/PPARα/CPT‐1A signaling pathway
Jiajun Han, Yuyang Miao, Linze Song, Xianfeng Zhou, Yan Liu, Lin Wang, Kai Zhu, He Ma, Yan Ma, Qingjie Li, Dong Han
The FASEB Journal.2025;[Epub] CrossRef
Integrated spatial multi‐omics profiling of Fusobacterium nucleatum in breast cancer unveils its role in tumour microenvironment modulation and cancer progression
Feng Zhao, Rui An, Yilei Ma, Shaobo Yu, Yuzhen Gao, Yanzhong Wang, Haitao Yu, Xinyou Xie, Jun Zhang
Clinical and Translational Medicine.2025;[Epub] CrossRef
G-quadruplex structural dynamics at MAPK12 promoter dictates transcriptional switch to determine stemness in breast cancer
Pallabi Sengupta, Anindya Dutta, Y. V. Suseela, Tanaya Roychowdhury, Nilanjan Banerjee, Ananya Dutta, Satyajit Halder, Kuladip Jana, Gopeswar Mukherjee, Samit Chattopadhyay, Thimmaiah Govindaraju, Subhrangsu Chatterjee
Cellular and Molecular Life Sciences.2024;[Epub] CrossRef
Natural products in osteoarthritis treatment: bridging basic research to clinical applications
Shunzheng Fang, Bin Zhang, Wei Xiang, Liujie Zheng, Xiaodong Wang, Song Li, Tongyi Zhang, Daibo Feng, Yunquan Gong, Jinhui Wu, Jing Yuan, Yaran Wu, Yizhen Zhu, Enli Liu, Zhenhong Ni
Chinese Medicine.2024;[Epub] CrossRef
Anti‐inflammatory, Antioxidative, and Moisturizing Effects of Oxyceros horridus Lour. Ethanol Extract in Human Keratinocytes via the p38 Signaling Pathway
Natasha Christabella Sutopo, Laily Rahmawati, Lei Huang, Masphal Kry, Phourin Chhang, Sarah Lee, Byoung‐Hee Lee, Jae Youl Cho
Chemistry & Biodiversity.2024;[Epub] CrossRef
Surface plasmon resonance based‐optical biosensor: Emerging diagnostic tool for early detection of diseases
Abhinay Kumar Singh, Masroor Anwar, Rashmita Pradhan, Mohd Suhail Ashar, Nitish Rai, Sharmistha Dey
Journal of Biophotonics.2023;[Epub] CrossRef
p38 mitogen‐activated protein kinase: Functions and targeted therapy in diseases
Qinwen Zheng, Shutong Li, Aoxue Wang, Man Zhe, Panpan Yang, Yongya Wu, Min Zhao, Yumeng Zhu, Yi Luo, Guan Wang, Liang Ouyang
MedComm – Oncology.2023;[Epub] CrossRef
Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention
Sharmistha Dey, Abhay Kumar Singh, Abhinay Kumar Singh, Kartik Rawat, Joyita Banerjee, Vertica Agnihotri, Deepak Upadhaya
Medical Oncology.2022;[Epub] CrossRef
Decursin prevents melanogenesis by suppressing MITF expression through the regulation of PKA/CREB, MAPKs, and PI3K/Akt/GSK-3β cascades
Hyungyeong Choi, Jeong-Hyun Yoon, Kumju Youn, Mira Jun
Biomedicine & Pharmacotherapy.2022; 147: 112651. CrossRef
Role of p38 MAP kinase in cancer stem cells and metastasis
Sriya Kudaravalli, Petra den Hollander, Sendurai A. Mani
Oncogene.2022; 41(23): 3177. CrossRef
Tim‐3 suppresses autoimmune hepatitis via the p38/MKP‐1 pathway in Th17 cells
Hongwei Wu, Shiyue Tang, Mengya Zhou, Jiji Xue, Zhenjun Yu, Jiansheng Zhu
FEBS Open Bio.2021; 11(5): 1406. CrossRef
A Special View of What Was Almost Forgotten: p38δ MAPK
Débora Bublitz Anton, Rodrigo Gay Ducati, Luís Fernando Saraiva Macedo Timmers, Stefan Laufer, Márcia Inês Goettert
Cancers.2021; 13(9): 2077. CrossRef
Atypical p38 Signaling, Activation, and Implications for Disease
Jeremy C. Burton, William Antoniades, Jennifer Okalova, Morgan M. Roos, Neil J. Grimsey
International Journal of Molecular Sciences.2021; 22(8): 4183. CrossRef
p38β - MAPK11 and its role in female cancers
Periklis Katopodis, Rachel Kerslake, Athanasios Zikopoulos, Nefeli Beri, Vladimir Anikin
Journal of Ovarian Research.2021;[Epub] CrossRef
The p38/MKP-1 signaling axis in oral cancer: Impact of tumor-associated macrophages
Zhenning Li, Fa-yu Liu, Keith L. Kirkwood
Oral Oncology.2020; 103: 104591. CrossRef
Secondary Squamous Cell Carcinoma of the Oral Cavity after Nasopharyngeal Carcinoma
Liyuan Dai, Qigen Fang, Peng Li, Junfu Wu, Xu Zhang
Cancer Research and Treatment.2020; 52(1): 109. CrossRef
p38β and Cancer: The Beginning of the Road
Olga Roche, Diego M. Fernández-Aroca, Elena Arconada-Luque, Natalia García-Flores, Liliana F. Mellor, María José Ruiz-Hidalgo, Ricardo Sánchez-Prieto
International Journal of Molecular Sciences.2020; 21(20): 7524. CrossRef

8,418 View
246 Download
19 Web of Science
17 Crossref

Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer: Seong-Hoon Yoon, Yoo-Duk Choi, In-Jae Oh, Kyu-Sik Kim, Hayoung Choi, Jinsun Chang, Hong-Joon Shin, Cheol-Kyu Park, Young-Chul Kim; Cancer Res Treat. 2015;47(4):661-669. Published online February 23, 2015; DOI: https://doi.org/10.4143/crt.2014.282

Abstract PDF PubReader ePub

Purpose
Direct sequencing (DS) is the standard method for detection of epidermal growth factor receptor (EGFR) gene mutation in non-small cell lung cancer (NSCLC); however, low detection sensitivity is a problem. The aim of this study is to demonstrate higher detection rate of EGFR gene mutation with peptide nucleic acid (PNA) clamping compared with DS. Materials and Methods This is a single arm, prospective study for patients with stage IIIB/IV or relapsed NSCLC. Using tumor DNA from 138 patients, both DS and PNA clamping for EGFR gene in exon 18, 19, 20, and 21 were performed. Discrepant results between the two methods were verified using Cobas and a mutant enrichment based next generation sequencing (NGS). Patients with activating mutations were treated with EGFR tyrosine kinase inhibitor (EGFR-TKI, gefitinib, or erlotinib) as first line treatment.
Results
Of 138 paired test sets, 24 (17.4%) and 45 (32.6%) cases with activating mutations were detected by DS and PNA clamping, respectively. The difference of detection rate between the two methods was 15.2% (95% confidence interval, 8.7% to 17.8%; p < 0.001). Between the two methods, 25 cases showed discrepant results (n=23, PNA+/DS–; n=2, PNA–/DS+). Mutations were confirmed by Cobas or NGS in 22 of 23 PNA+/DS– cases. The response rates to EGFR-TKI were 72.2% in the PNA+/DS+ group and 85.0% in the PNA+/DS– group. Conclusion PNA clamping showed a significantly higher detection rate of EGFR gene mutation compared with DS. Higher sensitivity of PNA clamping was not compromised by the loss of predictive power of response to EGFR-TKI.

Citations

Citations to this article as recorded by

Highly Sensitive Enrichment of Low-Frequency Variants by Hairpin Competition Amplification
Zhaocheng Liu, Rui Zhang, Xixi Jiang, Li Ji, Ping Sun, Yong Ji, Yu Zhang, Yan Ding, Koukou Li, Zhening Pu, Fengsheng Zhou, Jian Zou
Analytical Chemistry.2023; 95(32): 12015. CrossRef
Peptide Nucleic Acids: Recent Developments in the Synthesis and Backbone Modifications
Gurpreet Singh, Vikramdeep Monga
Bioorganic Chemistry.2023; 141: 106860. CrossRef
Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection
Hwa Park, Yoo Choi, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Joon Yoon, Chang-Seok Yoon, Hyung-Joo Oh, Young-Chul Kim, In-Jae Oh
Cancers.2023; 15(23): 5679. CrossRef
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
Hayoung Choi, Jae‐Kyeong Lee, Hyung‐Joo Oh, Min‐Seok Kim, Bo Gun Kho, Cheol Kyu Park, In‐Jae Oh, Young‐Chul Kim
Thoracic Cancer.2021; 12(10): 1598. CrossRef
Bronchial brushing cytology is comparable to bronchial biopsy for epidermal growth factor receptor mutation test in non-small cell lung cancer
Joo-Yeon Koo, Nah-Ihm Kim, Taebum Lee, Yoo-Duk Choi
Cytojournal.2020; 17: 16. CrossRef
Potential applications of peptide nucleic acid in biomedical domain
Kshitij RB Singh, Parikipandla Sridevi, Ravindra Pratap Singh
Engineering Reports.2020;[Epub] CrossRef
Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients
Insu Kim, Jung Seop Eom, Eun Jung Jo, Jeongha Mok.Ki Uk, Kwangha Lee, Ki Uk Kim, Hye‐Kyung Park, Min Ki Lee, Mi‐Hyun Kim
Thoracic Cancer.2019; 10(7): 1561. CrossRef
Sensitive detection of low-abundance in-frame deletions in EGFR exon 19 using novel wild-type blockers in real-time PCR
Xiao-Dong Ren, Ding-Yuan Liu, Hai-Qin Guo, Liu Wang, Na Zhao, Ning Su, Kun Wei, Sai Ren, Xue-Mei Qu, Xiao-Tian Dai, Qing Huang
Scientific Reports.2019;[Epub] CrossRef
Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis
Jae-Uk Song, Jonghoo Lee
Yonsei Medical Journal.2018; 59(2): 211. CrossRef
Comparative analysis of Adam33 mutations in murine lung cancer cell lines by droplet digital PCR, real-time PCR and Insight Onco™ NGS
Soo-Jin Kim, Eunhee Kim, Kyung-Taek Rim
Molecular & Cellular Toxicology.2018; 14(2): 221. CrossRef
Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
Tae‐Ok Kim, In‐Jae Oh, Bo Gun Kho, Ha Young Park, Jin Sun Chang, Cheol‐Kyu Park, Hong‐Joon Shin, Jung‐Hwan Lim, Yong‐Soo Kwon, Yu‐Il Kim, Sung‐Chul Lim, Young‐Chul Kim, Yoo‐Duk Choi
Thoracic Cancer.2018; 9(7): 856. CrossRef
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi
Clinical Lung Cancer.2018; 19(5): e775. CrossRef
Genetic Biomarkers and Their Applications to Prevent Occupational Diseases: A Literature Review
Kyung-Taek Rim
Toxicology and Environmental Health Sciences.2018; 10(3): 147. CrossRef
Molecular masquerading of rare EGFR L858M/L861R mutations as common L858R/L861Q mutations by PNA clamping assay
Ji Hyung Hong, Seung-Hyun Jung, Min Sung Kim, Sug Hyung Lee, Yeun-Jun Chung
Pathology.2017; 49(4): 453. CrossRef
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
Aeri Kim, Min Hye Jang, Soo Jung Lee, Young Kyung Bae
Journal of Breast Cancer.2017; 20(2): 150. CrossRef
Peptide nucleic acids: Advanced tools for biomedical applications
Anjali Gupta, Anuradha Mishra, Nidhi Puri
Journal of Biotechnology.2017; 259: 148. CrossRef
Non-invasive quantification of cell-free DNA mutations in plasma during lung tumor progression in mice
Soo-Jin Kim, Eunhee Kim, Kyung-Taek Rim
Cancer Biomarkers.2017; 20(4): 477. CrossRef
Peptide Nucleic Acid-Based Biosensors for Cancer Diagnosis
Roberta D’Agata, Maria Giuffrida, Giuseppe Spoto
Molecules.2017; 22(11): 1951. CrossRef
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
Mi-Young Park, Min Hee Jung, Eun Young Eo, Seokjoong Kim, Sang Hoon Lee, Yeon Joo Lee, Jong Sun Park, Young Jae Cho, Jin Haeng Chung, Cheol Hyeon Kim, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee
Oncotarget.2017; 8(22): 36331. CrossRef
Application of Peptide Nucleic Acid-based Assays Toward Detection of Somatic Mosaicism
Christopher S Hong, Chunzhang Yang, Zhengping Zhuang
Molecular Therapy - Nucleic Acids.2016; 5: e314. CrossRef
Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
Ha Young Park, Hyung Joo Oh, Ki‐Hyun Kim, Tae‐Ok Kim, Cheol‐Kyu Park, Hong‐Jun Shin, Jung‐Hwan Lim, Yong‐Soo Kwon, In‐Jae Oh, Yu‐Il Kim, Sung‐Chul Lim, Young‐Chul Kim, Yoo‐Duk Choi
Thoracic Cancer.2016; 7(6): 639. CrossRef
Association between GWAS-identified lung adenocarcinoma susceptibility loci andEGFRmutations in never-smoking Asian women, and comparison with findings from Western populations
Wei Jie Seow, Keitaro Matsuo, Chao Agnes Hsiung, Kouya Shiraishi, Minsun Song, Hee Nam Kim, Maria Pik Wong, Yun-Chul Hong, H. Dean Hosgood, Zhaoming Wang, I-Shou Chang, Jiu-Cun Wang, Nilanjan Chatterjee, Margaret Tucker, Hu Wei, Tetsuya Mitsudomi, Wei Zhe
Human Molecular Genetics.2016; : ddw414. CrossRef

13,011 View
174 Download
20 Web of Science
22 Crossref

Time-course Transcriptional Profiling of Human Amniotic Fluid-derived Stem Cells Using Microarray: Yong Wook Kim, Hyun-Jung Kim, Su-Mi Bae, Young Jae Kim, Jong-Chul Shin, Heung-Jae Chun, Jong-Won Rhie, Jiyoung Kim, Haekwon Kim, Woong Shick Ahn; Cancer Res Treat. 2010;42(2):82-94. Published online June 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.2.82

Abstract PDF PubReader ePub

Purpose

To maintain the homeostasis of stem cells and prevent their ability to initiate tumorigenesis, it is important to identify and modify factors that prevent or accelerate stem cell senescence. We used microarrays to attempt to identify such factors in human amniotic fluid (HAF)-derived stem cells.

Materials and Methods

To identify gene expression changes over a time course, we compared gene expression profiles of HAF-derived stem cells in different passages (1^st, 2^nd, 4^th, 6^th, 8^th, and 10^th) using a Sentrix Human illumina microarray.

Results

Of the 25,804 genes in the microarray chip, 1,970 showed an over 2-fold change relative to the control (the 1^st passage)-either upregulated or downregulated. Quantitative real-time PCR validated the microarray data for selected genes: markedly increased genes were CXCL12, cadherin 6 (CDH6), and folate receptor 3 (FOLR3). Downregulated genes included cyclin D2, keratin 8, insulin-like growth factor 2 (IGF2), natriuretic peptide precursor B (NPPB) and cellular retinoic acid binding protein 2 (CRABP2). The expression pattern of the selected genes was consistent with the microarray data except for CXCL12 and IGF2. Interestingly, the expression of NPPB was dramatically downregulated along the time course; it was almost completely shut-down by the 10^th passage. In contrast, FOLR3 mRNA expression was dramatically increased.

Conclusion

Taken together, although a function for NPPB and FOLR3 in stem cell senescence has not been reported, our results strongly suggest that NPPB and/or FOLR3 play a significant role in the regulation of stem cell senescence.

Citations

Citations to this article as recorded by

Recent Advances in Folates and Autoantibodies against Folate Receptors in Early Pregnancy and Miscarriage
Xue-Yun Qin, Si-Yao Ha, Lu Chen, Tao Zhang, Ming-Qing Li
Nutrients.2023; 15(23): 4882. CrossRef
Cancer Stem Cells: Emergent Nature of Tumor Emergency
Yaroslav R. Efremov, Anastasia S. Proskurina, Ekaterina A. Potter, Evgenia V. Dolgova, Oksana V. Efremova, Oleg S. Taranov, Aleksandr A. Ostanin, Elena R. Chernykh, Nikolay A. Kolchanov, Sergey S. Bogachev
Frontiers in Genetics.2018;[Epub] CrossRef
Systematic identification of an integrative network module during senescence from time-series gene expression
Chihyun Park, So Jeong Yun, Sung Jin Ryu, Soyoung Lee, Young-Sam Lee, Youngmi Yoon, Sang Chul Park
BMC Systems Biology.2017;[Epub] CrossRef
Isolation and Molecular Characterization of Amniotic Fluid-Derived Mesenchymal Stem Cells Obtained from Caesarean Sections
Lucas-Sebastian Spitzhorn, Md Shaifur Rahman, Laura Schwindt, Huyen-Tran Ho, Wasco Wruck, Martina Bohndorf, Silke Wehrmeyer, Audrey Ncube, Ines Beyer, Carsten Hagenbeck, Percy Balan, Tanja Fehm, James Adjaye
Stem Cells International.2017; 2017: 1. CrossRef
Scavenger receptor class A member 5 ( SCARA5 ) and suprabasin ( SBSN ) are hub genes of coexpression network modules associated with peripheral vein graft patency
Richard D. Kenagy, Mete Civelek, Shinsuke Kikuchi, Lihua Chen, Anthony Grieff, Michael Sobel, Aldons J. Lusis, Alexander W. Clowes
Journal of Vascular Surgery.2016; 64(1): 202. CrossRef
Amniotic Fluid-Derived Stem Cells (AFSC) and Their Application in Cell Therapy and Tissue Engineering
Syeda Zahra Anum, Seyed Raheel Muzavir, Ahmad Hassan, Amir Ali Khan, Aftab Ahmad
Razavi International Journal of Medicine.2015;[Epub] CrossRef
Simvastatin Modulates Mesenchymal Stromal Cell Proliferation and Gene Expression
Dalila Lucíola Zanette, Julio Cesar Cetrulo Lorenzi, Rodrigo Alexandre Panepucci, Patricia Vianna Bonini Palma, Daiane Fernanda dos Santos, Karen Lima Prata, Wilson Araújo Silva, Benedetta Bussolati
PLOS ONE.2015; 10(4): e0120137. CrossRef
Senescence and longevity in amniotic fluid derived cells
Z. Chen, A. Jadhav, F. Wang, M. Perle, R. Basch, B. K. Young
Stem Cell Discovery.2013; 03(01): 47. CrossRef
Amniotic Fluid and Amniotic Membrane Stem Cells: Marker Discovery
Maria G. Roubelakis, Ourania Trohatou, Nicholas P. Anagnou
Stem Cells International.2012; 2012: 1. CrossRef
Applications of Amniotic Membrane and Fluid in Stem Cell Biology and Regenerative Medicine
Kerry Rennie, Andrée Gruslin, Markus Hengstschläger, Duanqing Pei, Jinglei Cai, Toshio Nikaido, Mahmud Bani-Yaghoub
Stem Cells International.2012; 2012: 1. CrossRef

12,797 View
63 Download
10 Crossref

First
Prev
Page of 1
Next
Last

Search